An1791 personal page - To The Moon

An1791

No personal profile

0Follow

0Followers

0Topic

0Badge

2021-06-13

Ok

Software Provider Medallia Is Exploring a Potential Sale

2021-06-13

Good

Sorry, the original content has been removed

2021-06-13

Awesome

Sorry, the original content has been removed

2021-06-13

Alright

Sorry, the original content has been removed

2021-06-13

Wow

Biotech Finds Market Love at Last as Meme Traders, FDA Converge

2021-06-13

Sure

Moderna Says No Link Between COVID-19 Jab And Heart Inflammation

2021-06-13

Shine

Sorry, the original content has been removed

2021-06-13

Hmm

The Summer Movie Season Is Underway: Why That's Good News for AMC Stock

2021-06-13

Huat

S&P ekes out gains to close languid week

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3581933695162448","uuid":"3581933695162448","gmtCreate":1618839800636,"gmtModify":1618839800636,"name":"An1791","pinyin":"an1791","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":0,"tweetSize":9,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":1,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":182930215,"gmtCreate":1623549912937,"gmtModify":1704205834133,"author":{"id":"3581933695162448","authorId":"3581933695162448","name":"An1791","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581933695162448","idStr":"3581933695162448"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/182930215","repostId":"2142967204","repostType":4,"repost":{"id":"2142967204","kind":"news","pubTimestamp":1623431515,"share":"https://ttm.financial/m/news/2142967204?lang=&edition=fundamental","pubTime":"2021-06-12 01:11","market":"us","language":"en","title":"Software Provider Medallia Is Exploring a Potential Sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2142967204","media":"Bloomberg","summary":"(Bloomberg) -- Customer survey software provider Medallia Inc. is exploring options including a pote","content":"<p>(Bloomberg) -- Customer survey software provider Medallia Inc. is exploring options including a potential sale, according to people familiar with the matter.</p>\n<p>The San Francisco-based company is working with a financial adviser, said the people, who asked to not be identified because the matter isn’t public. Private equity firms have expressed interest in buying the company, the people added.</p>\n<p>No final decision has been made and Medallia could opt to remain independent. A representative for the company declined to comment.</p>\n<p>Medallia shares climbed as much as 13% in New York after a temporary halt to trading, valuing Medallia at about $5 billion.</p>\n<p><b>Tech Take-Privates</b></p>\n<p>Private equity firms have been busy buying tech companies this year.. Public software companies have announced multi billion-dollar buyouts in recent months, including <a href=\"https://laohu8.com/S/CLDR\">Cloudera Inc.</a> and <a href=\"https://laohu8.com/S/PFPT\">Proofpoint</a> Inc.</p>\n<p>Companies hire Medallia to run surveys for improving customer service, according to its website.</p>\n<p>It competes with <a href=\"https://laohu8.com/S/XM\">Qualtrics International</a> Inc., which <a href=\"https://laohu8.com/S/SAP\">SAP SE</a> spun off last year into an independent public company. Medallia went public in 2019, and trades about 30% above its initial public offering price.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Software Provider Medallia Is Exploring a Potential Sale</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSoftware Provider Medallia Is Exploring a Potential Sale\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-12 01:11 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/software-provider-medallia-exploring-potential-171155657.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Bloomberg) -- Customer survey software provider Medallia Inc. is exploring options including a potential sale, according to people familiar with the matter.\nThe San Francisco-based company is working...</p>\n\n<a href=\"https://finance.yahoo.com/news/software-provider-medallia-exploring-potential-171155657.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MDLA":"Medallia, Inc."},"source_url":"https://finance.yahoo.com/news/software-provider-medallia-exploring-potential-171155657.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2142967204","content_text":"(Bloomberg) -- Customer survey software provider Medallia Inc. is exploring options including a potential sale, according to people familiar with the matter.\nThe San Francisco-based company is working with a financial adviser, said the people, who asked to not be identified because the matter isn’t public. Private equity firms have expressed interest in buying the company, the people added.\nNo final decision has been made and Medallia could opt to remain independent. A representative for the company declined to comment.\nMedallia shares climbed as much as 13% in New York after a temporary halt to trading, valuing Medallia at about $5 billion.\nTech Take-Privates\nPrivate equity firms have been busy buying tech companies this year.. Public software companies have announced multi billion-dollar buyouts in recent months, including Cloudera Inc. and Proofpoint Inc.\nCompanies hire Medallia to run surveys for improving customer service, according to its website.\nIt competes with Qualtrics International Inc., which SAP SE spun off last year into an independent public company. Medallia went public in 2019, and trades about 30% above its initial public offering price.","news_type":1},"isVote":1,"tweetType":1,"viewCount":558,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":182997767,"gmtCreate":1623549898659,"gmtModify":1704205832680,"author":{"id":"3581933695162448","authorId":"3581933695162448","name":"An1791","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581933695162448","idStr":"3581933695162448"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/182997767","repostId":"2142204844","repostType":4,"isVote":1,"tweetType":1,"viewCount":308,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":182997002,"gmtCreate":1623549884306,"gmtModify":1704205831707,"author":{"id":"3581933695162448","authorId":"3581933695162448","name":"An1791","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581933695162448","idStr":"3581933695162448"},"themes":[],"htmlText":"Awesome","listText":"Awesome","text":"Awesome","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/182997002","repostId":"2142204650","repostType":4,"isVote":1,"tweetType":1,"viewCount":243,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":182994620,"gmtCreate":1623549868760,"gmtModify":1704205830737,"author":{"id":"3581933695162448","authorId":"3581933695162448","name":"An1791","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581933695162448","idStr":"3581933695162448"},"themes":[],"htmlText":"Alright","listText":"Alright","text":"Alright","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/182994620","repostId":"2142204450","repostType":4,"isVote":1,"tweetType":1,"viewCount":280,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":182995669,"gmtCreate":1623549854351,"gmtModify":1704205829280,"author":{"id":"3581933695162448","authorId":"3581933695162448","name":"An1791","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581933695162448","idStr":"3581933695162448"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/182995669","repostId":"2142025622","repostType":4,"repost":{"id":"2142025622","kind":"news","pubTimestamp":1623442528,"share":"https://ttm.financial/m/news/2142025622?lang=&edition=fundamental","pubTime":"2021-06-12 04:15","market":"us","language":"en","title":"Biotech Finds Market Love at Last as Meme Traders, FDA Converge","url":"https://stock-news.laohu8.com/highlight/detail?id=2142025622","media":"Bloomberg","summary":"(Bloomberg) -- Unloved biotech stocks posted the best week since November, fueled by a controversial","content":"<p><img src=\"https://static.tigerbbs.com/8cda5e1416d8765a6009019a2442b35a\" tg-width=\"1200\" tg-height=\"675\"></p>\n<p>(Bloomberg) -- Unloved biotech stocks posted the best week since November, fueled by a controversial regulatory decision and a legion of Reddit fans, burning a bunch of short sellers along the way. Now investors are taking a second look at the sector.</p>\n<p>With biotech having trailed the broader market for the past three months and chock full of companies that have been the focus of short sellers, it was catnip for the Reddit crowd. Indeed, the price action wrought havoc across the health-care sector after shorts lost over $465 million on Clover Health Investments Corp. in a single day as the stock nearly doubled.</p>\n<p>The moves weren’t just about amateur traders or punishing the shorts. Specialists who live and breathe biotech received two of three critical updates that have been hailed as the impetus for a broad return of investor interest. That includes approval from the Food and Drug Administration of an Alzheimer’s disease drug from Biogen Inc.</p>\n<p>“One of the clouds overhanging the sector went away this week, it’s a very good sign,” Brad Loncar, chief executive officer of Loncar Investments, said of the FDA decision.</p>\n<p>Monday’s decision by the FDA to approve Aduhelm, the first new medicine for the disease in decades, came despite mixed clinical trials, stunning analysts and buoying the sector. More than 15 million shares in the $11 billion <a href=\"https://laohu8.com/S/EEME\">iShares</a> Nasdaq Biotechnology ETF (IBB) changed hands, the highest daily level since June 2017. The index ended the week up 6%.</p>\n<p>It wasn’t all good news for these drugmakers. Aduhelm’s $56,000 a year price tag and a setback for Vertex Pharmaceuticals Inc. tempered the rally. The cost of the Biogen drug renewed concern about a regulatory clampdown on pricing, while Vertex announced that it had halted development of a liver disease treatment that the company said was unlikely to have a clinical benefit for patients. Shares of the drug developer plunged 11% on Friday and it’s the worst performer among large-cap biotechs, falling 18% so far this year.</p>\n<p>There’s <a href=\"https://laohu8.com/S/AONE\">one</a> more key readout biotech investors are waiting on: results from a trial in major depression from Biogen and its partner <a href=\"https://laohu8.com/S/SAGE\">Sage Therapeutics</a> Inc. With a win for Biogen and a loss for Vertex, the Biogen-Sage results could very well determine which direction biotech goes next, according to RBC analyst Brian Abrahams. The data are expected by the end of June.</p>\n<p>A recent Goldman Sachs survey of 75 investors at the bank’s health-care conference highlights the ongoing uncertainty, with 47% saying the sector would outperform over the second half of the year while the rest were evenly split between expecting health stocks to underperform or move in-line with the broader market.</p>\n<p><b>M&amp;A Hopes</b></p>\n<p>Vertex’s recent failure also came with a silver lining: the potential for a deal to bolster its pipeline. “Management has signaled a new openness to later-stage deals, and the shelving of VX-864 may now force its hand,” Bloomberg Intelligence analyst Marc Engelsgjerd wrote in a note.</p>\n<p>The pace of deals in the first half can determine the direction of biotechs for the rest of 2021, with years that start off with five or more deals over $500 million usually driving the outperformance of nearly 4% for the Nasdaq Biotech index, according to JPMorgan’s analysis.</p>\n<p>As biotech specialists weighed the catalysts for further gains, an 86% jump for Chamath Palihapitiya-backed health insurer Clover drove interest toward once high-flying biotechs with highly shorted floats and mediocre analyst ratings. <a href=\"https://laohu8.com/S/INO\">Inovio Pharmaceuticals Inc</a>., which recently lost U.S. government funding for its Covid shot, and <a href=\"https://laohu8.com/S/CLVS\">Clovis Oncology</a> Inc., a fallen former M&amp;A target with a disappointing cancer drug, popped this week as day traders targeted short-squeeze candidates.</p>\n<p>Retail traders have also been driving triple-digit and even quadruple-digit gains in obscure biotech names like Ocugen Inc., a drug developer with plans to bring a Covid-19 vaccine to the U.S., and <a href=\"https://laohu8.com/S/SAVA\">Cassava Sciences Inc</a>., a 20-year old biotech whose main product isn’t yet in the final stages of testing.</p>\n<p>Loncar at least is unfazed by biotechs joining the meme parade. “Professionals understand what the true intrinsic value of a biotech is,” he said in an interview. “Unlike GameStop or AMC, a biotech either has good science or it doesn’t.”</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biotech Finds Market Love at Last as Meme Traders, FDA Converge</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiotech Finds Market Love at Last as Meme Traders, FDA Converge\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-12 04:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/biotech-finds-market-love-last-201528495.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Bloomberg) -- Unloved biotech stocks posted the best week since November, fueled by a controversial regulatory decision and a legion of Reddit fans, burning a bunch of short sellers along the way. ...</p>\n\n<a href=\"https://finance.yahoo.com/news/biotech-finds-market-love-last-201528495.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VRTX":"福泰制药","BIIB":"渤健公司"},"source_url":"https://finance.yahoo.com/news/biotech-finds-market-love-last-201528495.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2142025622","content_text":"(Bloomberg) -- Unloved biotech stocks posted the best week since November, fueled by a controversial regulatory decision and a legion of Reddit fans, burning a bunch of short sellers along the way. Now investors are taking a second look at the sector.\nWith biotech having trailed the broader market for the past three months and chock full of companies that have been the focus of short sellers, it was catnip for the Reddit crowd. Indeed, the price action wrought havoc across the health-care sector after shorts lost over $465 million on Clover Health Investments Corp. in a single day as the stock nearly doubled.\nThe moves weren’t just about amateur traders or punishing the shorts. Specialists who live and breathe biotech received two of three critical updates that have been hailed as the impetus for a broad return of investor interest. That includes approval from the Food and Drug Administration of an Alzheimer’s disease drug from Biogen Inc.\n“One of the clouds overhanging the sector went away this week, it’s a very good sign,” Brad Loncar, chief executive officer of Loncar Investments, said of the FDA decision.\nMonday’s decision by the FDA to approve Aduhelm, the first new medicine for the disease in decades, came despite mixed clinical trials, stunning analysts and buoying the sector. More than 15 million shares in the $11 billion iShares Nasdaq Biotechnology ETF (IBB) changed hands, the highest daily level since June 2017. The index ended the week up 6%.\nIt wasn’t all good news for these drugmakers. Aduhelm’s $56,000 a year price tag and a setback for Vertex Pharmaceuticals Inc. tempered the rally. The cost of the Biogen drug renewed concern about a regulatory clampdown on pricing, while Vertex announced that it had halted development of a liver disease treatment that the company said was unlikely to have a clinical benefit for patients. Shares of the drug developer plunged 11% on Friday and it’s the worst performer among large-cap biotechs, falling 18% so far this year.\nThere’s one more key readout biotech investors are waiting on: results from a trial in major depression from Biogen and its partner Sage Therapeutics Inc. With a win for Biogen and a loss for Vertex, the Biogen-Sage results could very well determine which direction biotech goes next, according to RBC analyst Brian Abrahams. The data are expected by the end of June.\nA recent Goldman Sachs survey of 75 investors at the bank’s health-care conference highlights the ongoing uncertainty, with 47% saying the sector would outperform over the second half of the year while the rest were evenly split between expecting health stocks to underperform or move in-line with the broader market.\nM&A Hopes\nVertex’s recent failure also came with a silver lining: the potential for a deal to bolster its pipeline. “Management has signaled a new openness to later-stage deals, and the shelving of VX-864 may now force its hand,” Bloomberg Intelligence analyst Marc Engelsgjerd wrote in a note.\nThe pace of deals in the first half can determine the direction of biotechs for the rest of 2021, with years that start off with five or more deals over $500 million usually driving the outperformance of nearly 4% for the Nasdaq Biotech index, according to JPMorgan’s analysis.\nAs biotech specialists weighed the catalysts for further gains, an 86% jump for Chamath Palihapitiya-backed health insurer Clover drove interest toward once high-flying biotechs with highly shorted floats and mediocre analyst ratings. Inovio Pharmaceuticals Inc., which recently lost U.S. government funding for its Covid shot, and Clovis Oncology Inc., a fallen former M&A target with a disappointing cancer drug, popped this week as day traders targeted short-squeeze candidates.\nRetail traders have also been driving triple-digit and even quadruple-digit gains in obscure biotech names like Ocugen Inc., a drug developer with plans to bring a Covid-19 vaccine to the U.S., and Cassava Sciences Inc., a 20-year old biotech whose main product isn’t yet in the final stages of testing.\nLoncar at least is unfazed by biotechs joining the meme parade. “Professionals understand what the true intrinsic value of a biotech is,” he said in an interview. “Unlike GameStop or AMC, a biotech either has good science or it doesn’t.”","news_type":1},"isVote":1,"tweetType":1,"viewCount":316,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":182999922,"gmtCreate":1623549710566,"gmtModify":1704205820190,"author":{"id":"3581933695162448","authorId":"3581933695162448","name":"An1791","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581933695162448","idStr":"3581933695162448"},"themes":[],"htmlText":"Sure","listText":"Sure","text":"Sure","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/182999922","repostId":"2142024122","repostType":4,"repost":{"id":"2142024122","kind":"news","pubTimestamp":1623437876,"share":"https://ttm.financial/m/news/2142024122?lang=&edition=fundamental","pubTime":"2021-06-12 02:57","market":"us","language":"en","title":"Moderna Says No Link Between COVID-19 Jab And Heart Inflammation","url":"https://stock-news.laohu8.com/highlight/detail?id=2142024122","media":"Benzinga","summary":"Moderna Inc (NASDAQ: MRNA) says there is no “causal association” between its COVID-19 vaccine and ca","content":"<p><img src=\"https://static.tigerbbs.com/d1f671326f56d69d77095c4224c4a60a\" tg-width=\"600\" tg-height=\"400\" referrerpolicy=\"no-referrer\"></p>\n<p><b>Moderna Inc</b>&nbsp;(NASDAQ: MRNA) says there is no “causal association” between its COVID-19 vaccine and cases of myocarditis or pericarditis,&nbsp;based on a review of safety data.</p>\n<p>The Centers for Disease Control and Prevention (CDC) has identified 216 cases of heart inflammation after the first dose of an mRNA shot and another 573 cases after the second dose,&nbsp;Bloomberg reported.</p>\n<p>The median age of people with myocarditis or pericarditis following the first dose was 30 and 24 in the second-dose cases. There were 475 cases among people under 30.</p>\n<p>U.S. public health advisers will meet later this month to discuss a potential link between messenger RNA technology-based COVID-19 shots and heart inflammation.</p>\n<p>The technology is used by Moderna’s vaccine and&nbsp;<b>Pfizer Inc&nbsp;</b>(NYSE: PFE) -&nbsp;<b><a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>&nbsp;</b>(NASDAQ: BNTX).</p>\n<p>Moderna said it “will continue to monitor these reports closely and is actively working with public health and regulatory authorities to further assess this issue.”</p>\n<p>Earlier this month,&nbsp;Israel’s Health Ministry also reportedly found&nbsp;a small number of heart inflammation cases, observed mainly in young men who received the Pfizer COVID-19 vaccine in Israel, were likely linked to their vaccination.</p>\n<p><b>Price Action:</b>&nbsp;MRNA shares are down 0.59% at $215.73 during the market session on the last check Friday.</p>\n<p></p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Says No Link Between COVID-19 Jab And Heart Inflammation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Says No Link Between COVID-19 Jab And Heart Inflammation\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-12 02:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/moderna-says-no-between-covid-185756853.html><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna Inc (NASDAQ: MRNA) says there is no “causal association” between its COVID-19 vaccine and cases of myocarditis or pericarditis, based on a review of safety data.\nThe Centers for Disease ...</p>\n\n<a href=\"https://finance.yahoo.com/news/moderna-says-no-between-covid-185756853.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","PFE":"辉瑞","08237":"华星控股"},"source_url":"https://finance.yahoo.com/news/moderna-says-no-between-covid-185756853.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2142024122","content_text":"Moderna Inc (NASDAQ: MRNA) says there is no “causal association” between its COVID-19 vaccine and cases of myocarditis or pericarditis, based on a review of safety data.\nThe Centers for Disease Control and Prevention (CDC) has identified 216 cases of heart inflammation after the first dose of an mRNA shot and another 573 cases after the second dose, Bloomberg reported.\nThe median age of people with myocarditis or pericarditis following the first dose was 30 and 24 in the second-dose cases. There were 475 cases among people under 30.\nU.S. public health advisers will meet later this month to discuss a potential link between messenger RNA technology-based COVID-19 shots and heart inflammation.\nThe technology is used by Moderna’s vaccine and Pfizer Inc (NYSE: PFE) - BioNTech SE (NASDAQ: BNTX).\nModerna said it “will continue to monitor these reports closely and is actively working with public health and regulatory authorities to further assess this issue.”\nEarlier this month, Israel’s Health Ministry also reportedly found a small number of heart inflammation cases, observed mainly in young men who received the Pfizer COVID-19 vaccine in Israel, were likely linked to their vaccination.\nPrice Action: MRNA shares are down 0.59% at $215.73 during the market session on the last check Friday.","news_type":1},"isVote":1,"tweetType":1,"viewCount":283,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":182904605,"gmtCreate":1623549665207,"gmtModify":1704205816637,"author":{"id":"3581933695162448","authorId":"3581933695162448","name":"An1791","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581933695162448","idStr":"3581933695162448"},"themes":[],"htmlText":"Shine","listText":"Shine","text":"Shine","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/182904605","repostId":"2142342202","repostType":4,"isVote":1,"tweetType":1,"viewCount":199,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":182903289,"gmtCreate":1623549472041,"gmtModify":1704205807888,"author":{"id":"3581933695162448","authorId":"3581933695162448","name":"An1791","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581933695162448","idStr":"3581933695162448"},"themes":[],"htmlText":"Hmm","listText":"Hmm","text":"Hmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/182903289","repostId":"2142788457","repostType":4,"repost":{"id":"2142788457","kind":"highlight","pubTimestamp":1623506400,"share":"https://ttm.financial/m/news/2142788457?lang=&edition=fundamental","pubTime":"2021-06-12 22:00","market":"us","language":"en","title":"The Summer Movie Season Is Underway: Why That's Good News for AMC Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2142788457","media":"Motley Fool","summary":"AMC is best known for its part in the meme stock-trading frenzy, but its business is slowly recovering.","content":"<p><b>AMC</b> <b>Entertainment</b> (NYSE:AMC) stock has experienced some violent price movements in the last several months -- its price recently came close to doubling in a single day. The stock has been the subject of a virtual tug of war between retail traders and Wall Street, with each side betting on an opposite outcome in AMC's stock price. So far, the retail traders are crushing Wall Street: AMC stock is up 2,230% year to date as of Friday's close. To add fuel to that fire, the summer movie season is under way, and with coronavirus trends all moving in a positive direction in the U.S., AMC could experience a surge in viewers.</p>\n<p><img src=\"https://static.tigerbbs.com/4bb531efbf81e26901c99419e60ac186\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>AMC stock is up nearly 2,500% in 2021. Image source: Getty Images.</p>\n<h3>Seats are filling up in AMC theaters again</h3>\n<p>The summer movie season is off to a great start with the release of two new films: <i>A Quite Place 2 </i>and<i> Cruella. </i>That's just about as good as it can get considering the circumstances. Although nearly all of AMC's theaters have reopened in the U.S, significant capacity restrictions remain.</p>\n<p>In roughly two weeks since its release, <b>Walt Disney</b>'s&nbsp;<i>Cruella</i> has grossed $86.8 million at the box office worldwide despite being also available on Disney+ (for an additional fee of $29.99 to subscribers). Thus far, the reasonably robust box office total, under restricted seating capacity and a simultaneous release on a streaming service, is good news for AMC.</p>\n<p>In contrast, <i>A Quiet Place 2</i> is opening under a 45-day exclusive theatrical window. Box office totals for the film, released on the same weekend as <i>Cruella,</i> come to $138 million worldwide.</p>\n<p>The outperformance of <i>A Quiet Place 2</i> could be due to the film's exclusive availability at theaters. However, it would be reasonable to expect some folks deciding to watch <i>Cruella</i> on Disney+. Still, getting visitors back inside movie theaters is a win for AMC.</p>\n<p>Moreover, <i>F9: The Fast Saga</i>, another part of the successful <i>Fast and Furious</i> film franchise, is set to be released in U.S. theaters on June 25. The ninth installment has already been successful elsewhere in the world, grossing over $250 million at the international box office.</p>\n<p>With a few more blockbusters coming into theaters soon, this could be a summer of recovery for AMC.</p>\n<h3>What this could mean for investors</h3>\n<p>That could be a huge gain for the company's efforts in removing cash flow problems. AMC burned through $312.9 million in cash in the most recent quarter. That's a rate of about $104 million per month. AMC has to pay rent on its movie theaters whether it has people in the seats or not. Since most of its costs are fixed, getting viewers in attendance generates positive cash flow for AMC even if it remains in negative net-income territory.</p>\n<p>On average, an AMC moviegoer spends 72% of the price of a ticket on food and beverage. Add in the fact that AMC makes more in operating profit from viewers buying food and beverage than it does from ticket sales, and AMC could be generating positive cash flow from operations by the end of the second quarter. That is, of course, if there are no further disruptions from a resurgence of coronavirus cases.</p>\n<p>The increase in cash flow, combined with the $1.246 billion in equity capital it has raised in recent months, should go a long way toward shoring up AMC's balance sheet and giving the battered movie theater chain more time to recover from the devastations of the coronavirus pandemic. And that should give the millions of retail investors rooting for the success of AMC stock something to cheer about.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Summer Movie Season Is Underway: Why That's Good News for AMC Stock</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Summer Movie Season Is Underway: Why That's Good News for AMC Stock\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-12 22:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/12/the-summer-movie-season-is-underway-why-thats-good/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AMC Entertainment (NYSE:AMC) stock has experienced some violent price movements in the last several months -- its price recently came close to doubling in a single day. The stock has been the subject ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/12/the-summer-movie-season-is-underway-why-thats-good/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMC":"AMC院线","NWS":"新闻集团"},"source_url":"https://www.fool.com/investing/2021/06/12/the-summer-movie-season-is-underway-why-thats-good/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2142788457","content_text":"AMC Entertainment (NYSE:AMC) stock has experienced some violent price movements in the last several months -- its price recently came close to doubling in a single day. The stock has been the subject of a virtual tug of war between retail traders and Wall Street, with each side betting on an opposite outcome in AMC's stock price. So far, the retail traders are crushing Wall Street: AMC stock is up 2,230% year to date as of Friday's close. To add fuel to that fire, the summer movie season is under way, and with coronavirus trends all moving in a positive direction in the U.S., AMC could experience a surge in viewers.\n\nAMC stock is up nearly 2,500% in 2021. Image source: Getty Images.\nSeats are filling up in AMC theaters again\nThe summer movie season is off to a great start with the release of two new films: A Quite Place 2 and Cruella. That's just about as good as it can get considering the circumstances. Although nearly all of AMC's theaters have reopened in the U.S, significant capacity restrictions remain.\nIn roughly two weeks since its release, Walt Disney's Cruella has grossed $86.8 million at the box office worldwide despite being also available on Disney+ (for an additional fee of $29.99 to subscribers). Thus far, the reasonably robust box office total, under restricted seating capacity and a simultaneous release on a streaming service, is good news for AMC.\nIn contrast, A Quiet Place 2 is opening under a 45-day exclusive theatrical window. Box office totals for the film, released on the same weekend as Cruella, come to $138 million worldwide.\nThe outperformance of A Quiet Place 2 could be due to the film's exclusive availability at theaters. However, it would be reasonable to expect some folks deciding to watch Cruella on Disney+. Still, getting visitors back inside movie theaters is a win for AMC.\nMoreover, F9: The Fast Saga, another part of the successful Fast and Furious film franchise, is set to be released in U.S. theaters on June 25. The ninth installment has already been successful elsewhere in the world, grossing over $250 million at the international box office.\nWith a few more blockbusters coming into theaters soon, this could be a summer of recovery for AMC.\nWhat this could mean for investors\nThat could be a huge gain for the company's efforts in removing cash flow problems. AMC burned through $312.9 million in cash in the most recent quarter. That's a rate of about $104 million per month. AMC has to pay rent on its movie theaters whether it has people in the seats or not. Since most of its costs are fixed, getting viewers in attendance generates positive cash flow for AMC even if it remains in negative net-income territory.\nOn average, an AMC moviegoer spends 72% of the price of a ticket on food and beverage. Add in the fact that AMC makes more in operating profit from viewers buying food and beverage than it does from ticket sales, and AMC could be generating positive cash flow from operations by the end of the second quarter. That is, of course, if there are no further disruptions from a resurgence of coronavirus cases.\nThe increase in cash flow, combined with the $1.246 billion in equity capital it has raised in recent months, should go a long way toward shoring up AMC's balance sheet and giving the battered movie theater chain more time to recover from the devastations of the coronavirus pandemic. And that should give the millions of retail investors rooting for the success of AMC stock something to cheer about.","news_type":1},"isVote":1,"tweetType":1,"viewCount":354,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":182074982,"gmtCreate":1623549292246,"gmtModify":1704205801711,"author":{"id":"3581933695162448","authorId":"3581933695162448","name":"An1791","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581933695162448","idStr":"3581933695162448"},"themes":[],"htmlText":"Huat","listText":"Huat","text":"Huat","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/182074982","repostId":"2142204074","repostType":4,"repost":{"id":"2142204074","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1623441637,"share":"https://ttm.financial/m/news/2142204074?lang=&edition=fundamental","pubTime":"2021-06-12 04:00","market":"us","language":"en","title":"S&P ekes out gains to close languid week","url":"https://stock-news.laohu8.com/highlight/detail?id=2142204074","media":"Reuters","summary":"NEW YORK, June 11  - The S&P 500 closed nominally higher at the end of a torpid week marked with few market-moving catalysts and persistent concerns over whether current inflation spikes could linger and cause the U.S. Federal Reserve to tighten its dovish policy sooner than expected.Economically sensitive smallcaps and transports notched solid gains, outperforming the broader market.For the week, the S&P and the Nasdaq advanced from last Friday's close, while the Dow posted a weekly loss.But th","content":"<p>NEW YORK, June 11 (Reuters) - The S&amp;P 500 closed nominally higher at the end of a torpid week marked with few market-moving catalysts and persistent concerns over whether current inflation spikes could linger and cause the U.S. Federal Reserve to tighten its dovish policy sooner than expected.</p>\n<p>Economically sensitive smallcaps and transports&nbsp;notched solid gains, outperforming the broader market.</p>\n<p>For the week, the S&amp;P and the Nasdaq advanced from last Friday's close, while the Dow posted a weekly loss.</p>\n<p>But the indexes have been range-bound, with few catalysts to move investor sentiment. Much of the focus centered on Thursday's consumer price data, which eased jitters over the duration of the current inflation wave.</p>\n<p>\"It’s a muted day today,\" Oliver Pursche, senior vice president at Wealthspire Advisors, in New York. \"The summer is settling in, people are slipping out of work early and there’s nothing in the news that’s going to materially drive the market in either direction.\"</p>\n<p>\"So, investors are going to wait until earnings season.\"</p>\n<p>The Federal Reserve has repeatedly said that near-term price surges will not metastasize into lasting inflation, an assertion reflected in the University of Michigan's Consumer Sentiment report released on Friday, which showed inflation expectations easing from last month's spike.</p>\n<p>Investors now turn their attention to the Fed's statement at the conclusion of next week's two-day monetary policy meeting, which will be parsed for clues regarding the central bank's timetable for raising key interest rates.</p>\n<p>\"Our view continues to be that inflationary data is transient and we will be around the 2% mark for the year,\" Pursche added.</p>\n<p>Benchmark U.S. Treasury yields posted their biggest weekly drop in nearly a year, weighing on the interest-sensitive financial sector in recent sessions.</p>\n<p>The Food and Drug Administration is facing mounting criticism over its \"accelerated approval\" of Biogen Inc's</p>\n<p>Alzheimer's drug Aduhelm without strong evidence of its ability to combat the disease.</p>\n<p>Biogen shares, along with the broader healthcare sector&nbsp;ended the session lower.</p>\n<p>Unofficially, the Dow Jones Industrial Average rose 14.41 points, or 0.04%, to 34,480.65, the S&amp;P 500 gained 8.29 points, or 0.20%, to 4,247.47 and the Nasdaq Composite&nbsp;added 49.09 points, or 0.35%, to 14,069.42.</p>\n<p>Among the 11 major sectors in the S&amp;P 500, healthcare suffered the biggest percentage drop.</p>\n<p>Much of the trading volume this week was attributable to the ongoing social media-driven \"meme stock\" phenomenon, in which retail investors swarm around heavily shorted stocks.</p>\n<p>But meme stock moves were more muted on Friday, with AMC Entertainment outperforming.</p>\n<p>(Reporting by Stephen Culp in New York Additional reporting by Ambar Warrick and Devik Jain in Bengaluru Editing by Matthew Lewis and Cynthia Osterman)</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>S&P ekes out gains to close languid week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nS&P ekes out gains to close languid week\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-06-12 04:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>NEW YORK, June 11 (Reuters) - The S&amp;P 500 closed nominally higher at the end of a torpid week marked with few market-moving catalysts and persistent concerns over whether current inflation spikes could linger and cause the U.S. Federal Reserve to tighten its dovish policy sooner than expected.</p>\n<p>Economically sensitive smallcaps and transports&nbsp;notched solid gains, outperforming the broader market.</p>\n<p>For the week, the S&amp;P and the Nasdaq advanced from last Friday's close, while the Dow posted a weekly loss.</p>\n<p>But the indexes have been range-bound, with few catalysts to move investor sentiment. Much of the focus centered on Thursday's consumer price data, which eased jitters over the duration of the current inflation wave.</p>\n<p>\"It’s a muted day today,\" Oliver Pursche, senior vice president at Wealthspire Advisors, in New York. \"The summer is settling in, people are slipping out of work early and there’s nothing in the news that’s going to materially drive the market in either direction.\"</p>\n<p>\"So, investors are going to wait until earnings season.\"</p>\n<p>The Federal Reserve has repeatedly said that near-term price surges will not metastasize into lasting inflation, an assertion reflected in the University of Michigan's Consumer Sentiment report released on Friday, which showed inflation expectations easing from last month's spike.</p>\n<p>Investors now turn their attention to the Fed's statement at the conclusion of next week's two-day monetary policy meeting, which will be parsed for clues regarding the central bank's timetable for raising key interest rates.</p>\n<p>\"Our view continues to be that inflationary data is transient and we will be around the 2% mark for the year,\" Pursche added.</p>\n<p>Benchmark U.S. Treasury yields posted their biggest weekly drop in nearly a year, weighing on the interest-sensitive financial sector in recent sessions.</p>\n<p>The Food and Drug Administration is facing mounting criticism over its \"accelerated approval\" of Biogen Inc's</p>\n<p>Alzheimer's drug Aduhelm without strong evidence of its ability to combat the disease.</p>\n<p>Biogen shares, along with the broader healthcare sector&nbsp;ended the session lower.</p>\n<p>Unofficially, the Dow Jones Industrial Average rose 14.41 points, or 0.04%, to 34,480.65, the S&amp;P 500 gained 8.29 points, or 0.20%, to 4,247.47 and the Nasdaq Composite&nbsp;added 49.09 points, or 0.35%, to 14,069.42.</p>\n<p>Among the 11 major sectors in the S&amp;P 500, healthcare suffered the biggest percentage drop.</p>\n<p>Much of the trading volume this week was attributable to the ongoing social media-driven \"meme stock\" phenomenon, in which retail investors swarm around heavily shorted stocks.</p>\n<p>But meme stock moves were more muted on Friday, with AMC Entertainment outperforming.</p>\n<p>(Reporting by Stephen Culp in New York Additional reporting by Ambar Warrick and Devik Jain in Bengaluru Editing by Matthew Lewis and Cynthia Osterman)</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"161125":"标普500","513500":"标普500ETF","DJX":"1/100道琼斯","DXD":"道指两倍做空ETF","QID":"纳指两倍做空ETF","TQQQ":"纳指三倍做多ETF","DDM":"道指两倍做多ETF","SH":"标普500反向ETF",".SPX":"S&P 500 Index","PSQ":"纳指反向ETF","QLD":"纳指两倍做多ETF","IVV":"标普500指数ETF","DOG":"道指反向ETF","UDOW":"道指三倍做多ETF-ProShares",".IXIC":"NASDAQ Composite","SSO":"两倍做多标普500ETF","UPRO":"三倍做多标普500ETF","SPXU":"三倍做空标普500ETF","SQQQ":"纳指三倍做空ETF","OEX":"标普100","SDOW":"道指三倍做空ETF-ProShares","OEF":"标普100指数ETF-iShares","QQQ":"纳指100ETF",".DJI":"道琼斯","SDS":"两倍做空标普500ETF"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2142204074","content_text":"NEW YORK, June 11 (Reuters) - The S&P 500 closed nominally higher at the end of a torpid week marked with few market-moving catalysts and persistent concerns over whether current inflation spikes could linger and cause the U.S. Federal Reserve to tighten its dovish policy sooner than expected.\nEconomically sensitive smallcaps and transports notched solid gains, outperforming the broader market.\nFor the week, the S&P and the Nasdaq advanced from last Friday's close, while the Dow posted a weekly loss.\nBut the indexes have been range-bound, with few catalysts to move investor sentiment. Much of the focus centered on Thursday's consumer price data, which eased jitters over the duration of the current inflation wave.\n\"It’s a muted day today,\" Oliver Pursche, senior vice president at Wealthspire Advisors, in New York. \"The summer is settling in, people are slipping out of work early and there’s nothing in the news that’s going to materially drive the market in either direction.\"\n\"So, investors are going to wait until earnings season.\"\nThe Federal Reserve has repeatedly said that near-term price surges will not metastasize into lasting inflation, an assertion reflected in the University of Michigan's Consumer Sentiment report released on Friday, which showed inflation expectations easing from last month's spike.\nInvestors now turn their attention to the Fed's statement at the conclusion of next week's two-day monetary policy meeting, which will be parsed for clues regarding the central bank's timetable for raising key interest rates.\n\"Our view continues to be that inflationary data is transient and we will be around the 2% mark for the year,\" Pursche added.\nBenchmark U.S. Treasury yields posted their biggest weekly drop in nearly a year, weighing on the interest-sensitive financial sector in recent sessions.\nThe Food and Drug Administration is facing mounting criticism over its \"accelerated approval\" of Biogen Inc's\nAlzheimer's drug Aduhelm without strong evidence of its ability to combat the disease.\nBiogen shares, along with the broader healthcare sector ended the session lower.\nUnofficially, the Dow Jones Industrial Average rose 14.41 points, or 0.04%, to 34,480.65, the S&P 500 gained 8.29 points, or 0.20%, to 4,247.47 and the Nasdaq Composite added 49.09 points, or 0.35%, to 14,069.42.\nAmong the 11 major sectors in the S&P 500, healthcare suffered the biggest percentage drop.\nMuch of the trading volume this week was attributable to the ongoing social media-driven \"meme stock\" phenomenon, in which retail investors swarm around heavily shorted stocks.\nBut meme stock moves were more muted on Friday, with AMC Entertainment outperforming.\n(Reporting by Stephen Culp in New York Additional reporting by Ambar Warrick and Devik Jain in Bengaluru Editing by Matthew Lewis and Cynthia Osterman)","news_type":1},"isVote":1,"tweetType":1,"viewCount":234,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":182074982,"gmtCreate":1623549292246,"gmtModify":1704205801711,"author":{"id":"3581933695162448","authorId":"3581933695162448","name":"An1791","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581933695162448","authorIdStr":"3581933695162448"},"themes":[],"htmlText":"Huat","listText":"Huat","text":"Huat","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/182074982","repostId":"2142204074","repostType":4,"repost":{"id":"2142204074","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1623441637,"share":"https://ttm.financial/m/news/2142204074?lang=&edition=fundamental","pubTime":"2021-06-12 04:00","market":"us","language":"en","title":"S&P ekes out gains to close languid week","url":"https://stock-news.laohu8.com/highlight/detail?id=2142204074","media":"Reuters","summary":"NEW YORK, June 11  - The S&P 500 closed nominally higher at the end of a torpid week marked with few market-moving catalysts and persistent concerns over whether current inflation spikes could linger and cause the U.S. Federal Reserve to tighten its dovish policy sooner than expected.Economically sensitive smallcaps and transports notched solid gains, outperforming the broader market.For the week, the S&P and the Nasdaq advanced from last Friday's close, while the Dow posted a weekly loss.But th","content":"<p>NEW YORK, June 11 (Reuters) - The S&amp;P 500 closed nominally higher at the end of a torpid week marked with few market-moving catalysts and persistent concerns over whether current inflation spikes could linger and cause the U.S. Federal Reserve to tighten its dovish policy sooner than expected.</p>\n<p>Economically sensitive smallcaps and transports&nbsp;notched solid gains, outperforming the broader market.</p>\n<p>For the week, the S&amp;P and the Nasdaq advanced from last Friday's close, while the Dow posted a weekly loss.</p>\n<p>But the indexes have been range-bound, with few catalysts to move investor sentiment. Much of the focus centered on Thursday's consumer price data, which eased jitters over the duration of the current inflation wave.</p>\n<p>\"It’s a muted day today,\" Oliver Pursche, senior vice president at Wealthspire Advisors, in New York. \"The summer is settling in, people are slipping out of work early and there’s nothing in the news that’s going to materially drive the market in either direction.\"</p>\n<p>\"So, investors are going to wait until earnings season.\"</p>\n<p>The Federal Reserve has repeatedly said that near-term price surges will not metastasize into lasting inflation, an assertion reflected in the University of Michigan's Consumer Sentiment report released on Friday, which showed inflation expectations easing from last month's spike.</p>\n<p>Investors now turn their attention to the Fed's statement at the conclusion of next week's two-day monetary policy meeting, which will be parsed for clues regarding the central bank's timetable for raising key interest rates.</p>\n<p>\"Our view continues to be that inflationary data is transient and we will be around the 2% mark for the year,\" Pursche added.</p>\n<p>Benchmark U.S. Treasury yields posted their biggest weekly drop in nearly a year, weighing on the interest-sensitive financial sector in recent sessions.</p>\n<p>The Food and Drug Administration is facing mounting criticism over its \"accelerated approval\" of Biogen Inc's</p>\n<p>Alzheimer's drug Aduhelm without strong evidence of its ability to combat the disease.</p>\n<p>Biogen shares, along with the broader healthcare sector&nbsp;ended the session lower.</p>\n<p>Unofficially, the Dow Jones Industrial Average rose 14.41 points, or 0.04%, to 34,480.65, the S&amp;P 500 gained 8.29 points, or 0.20%, to 4,247.47 and the Nasdaq Composite&nbsp;added 49.09 points, or 0.35%, to 14,069.42.</p>\n<p>Among the 11 major sectors in the S&amp;P 500, healthcare suffered the biggest percentage drop.</p>\n<p>Much of the trading volume this week was attributable to the ongoing social media-driven \"meme stock\" phenomenon, in which retail investors swarm around heavily shorted stocks.</p>\n<p>But meme stock moves were more muted on Friday, with AMC Entertainment outperforming.</p>\n<p>(Reporting by Stephen Culp in New York Additional reporting by Ambar Warrick and Devik Jain in Bengaluru Editing by Matthew Lewis and Cynthia Osterman)</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>S&P ekes out gains to close languid week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nS&P ekes out gains to close languid week\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-06-12 04:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>NEW YORK, June 11 (Reuters) - The S&amp;P 500 closed nominally higher at the end of a torpid week marked with few market-moving catalysts and persistent concerns over whether current inflation spikes could linger and cause the U.S. Federal Reserve to tighten its dovish policy sooner than expected.</p>\n<p>Economically sensitive smallcaps and transports&nbsp;notched solid gains, outperforming the broader market.</p>\n<p>For the week, the S&amp;P and the Nasdaq advanced from last Friday's close, while the Dow posted a weekly loss.</p>\n<p>But the indexes have been range-bound, with few catalysts to move investor sentiment. Much of the focus centered on Thursday's consumer price data, which eased jitters over the duration of the current inflation wave.</p>\n<p>\"It’s a muted day today,\" Oliver Pursche, senior vice president at Wealthspire Advisors, in New York. \"The summer is settling in, people are slipping out of work early and there’s nothing in the news that’s going to materially drive the market in either direction.\"</p>\n<p>\"So, investors are going to wait until earnings season.\"</p>\n<p>The Federal Reserve has repeatedly said that near-term price surges will not metastasize into lasting inflation, an assertion reflected in the University of Michigan's Consumer Sentiment report released on Friday, which showed inflation expectations easing from last month's spike.</p>\n<p>Investors now turn their attention to the Fed's statement at the conclusion of next week's two-day monetary policy meeting, which will be parsed for clues regarding the central bank's timetable for raising key interest rates.</p>\n<p>\"Our view continues to be that inflationary data is transient and we will be around the 2% mark for the year,\" Pursche added.</p>\n<p>Benchmark U.S. Treasury yields posted their biggest weekly drop in nearly a year, weighing on the interest-sensitive financial sector in recent sessions.</p>\n<p>The Food and Drug Administration is facing mounting criticism over its \"accelerated approval\" of Biogen Inc's</p>\n<p>Alzheimer's drug Aduhelm without strong evidence of its ability to combat the disease.</p>\n<p>Biogen shares, along with the broader healthcare sector&nbsp;ended the session lower.</p>\n<p>Unofficially, the Dow Jones Industrial Average rose 14.41 points, or 0.04%, to 34,480.65, the S&amp;P 500 gained 8.29 points, or 0.20%, to 4,247.47 and the Nasdaq Composite&nbsp;added 49.09 points, or 0.35%, to 14,069.42.</p>\n<p>Among the 11 major sectors in the S&amp;P 500, healthcare suffered the biggest percentage drop.</p>\n<p>Much of the trading volume this week was attributable to the ongoing social media-driven \"meme stock\" phenomenon, in which retail investors swarm around heavily shorted stocks.</p>\n<p>But meme stock moves were more muted on Friday, with AMC Entertainment outperforming.</p>\n<p>(Reporting by Stephen Culp in New York Additional reporting by Ambar Warrick and Devik Jain in Bengaluru Editing by Matthew Lewis and Cynthia Osterman)</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"161125":"标普500","513500":"标普500ETF","DJX":"1/100道琼斯","DXD":"道指两倍做空ETF","QID":"纳指两倍做空ETF","TQQQ":"纳指三倍做多ETF","DDM":"道指两倍做多ETF","SH":"标普500反向ETF",".SPX":"S&P 500 Index","PSQ":"纳指反向ETF","QLD":"纳指两倍做多ETF","IVV":"标普500指数ETF","DOG":"道指反向ETF","UDOW":"道指三倍做多ETF-ProShares",".IXIC":"NASDAQ Composite","SSO":"两倍做多标普500ETF","UPRO":"三倍做多标普500ETF","SPXU":"三倍做空标普500ETF","SQQQ":"纳指三倍做空ETF","OEX":"标普100","SDOW":"道指三倍做空ETF-ProShares","OEF":"标普100指数ETF-iShares","QQQ":"纳指100ETF",".DJI":"道琼斯","SDS":"两倍做空标普500ETF"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2142204074","content_text":"NEW YORK, June 11 (Reuters) - The S&P 500 closed nominally higher at the end of a torpid week marked with few market-moving catalysts and persistent concerns over whether current inflation spikes could linger and cause the U.S. Federal Reserve to tighten its dovish policy sooner than expected.\nEconomically sensitive smallcaps and transports notched solid gains, outperforming the broader market.\nFor the week, the S&P and the Nasdaq advanced from last Friday's close, while the Dow posted a weekly loss.\nBut the indexes have been range-bound, with few catalysts to move investor sentiment. Much of the focus centered on Thursday's consumer price data, which eased jitters over the duration of the current inflation wave.\n\"It’s a muted day today,\" Oliver Pursche, senior vice president at Wealthspire Advisors, in New York. \"The summer is settling in, people are slipping out of work early and there’s nothing in the news that’s going to materially drive the market in either direction.\"\n\"So, investors are going to wait until earnings season.\"\nThe Federal Reserve has repeatedly said that near-term price surges will not metastasize into lasting inflation, an assertion reflected in the University of Michigan's Consumer Sentiment report released on Friday, which showed inflation expectations easing from last month's spike.\nInvestors now turn their attention to the Fed's statement at the conclusion of next week's two-day monetary policy meeting, which will be parsed for clues regarding the central bank's timetable for raising key interest rates.\n\"Our view continues to be that inflationary data is transient and we will be around the 2% mark for the year,\" Pursche added.\nBenchmark U.S. Treasury yields posted their biggest weekly drop in nearly a year, weighing on the interest-sensitive financial sector in recent sessions.\nThe Food and Drug Administration is facing mounting criticism over its \"accelerated approval\" of Biogen Inc's\nAlzheimer's drug Aduhelm without strong evidence of its ability to combat the disease.\nBiogen shares, along with the broader healthcare sector ended the session lower.\nUnofficially, the Dow Jones Industrial Average rose 14.41 points, or 0.04%, to 34,480.65, the S&P 500 gained 8.29 points, or 0.20%, to 4,247.47 and the Nasdaq Composite added 49.09 points, or 0.35%, to 14,069.42.\nAmong the 11 major sectors in the S&P 500, healthcare suffered the biggest percentage drop.\nMuch of the trading volume this week was attributable to the ongoing social media-driven \"meme stock\" phenomenon, in which retail investors swarm around heavily shorted stocks.\nBut meme stock moves were more muted on Friday, with AMC Entertainment outperforming.\n(Reporting by Stephen Culp in New York Additional reporting by Ambar Warrick and Devik Jain in Bengaluru Editing by Matthew Lewis and Cynthia Osterman)","news_type":1},"isVote":1,"tweetType":1,"viewCount":234,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":182930215,"gmtCreate":1623549912937,"gmtModify":1704205834133,"author":{"id":"3581933695162448","authorId":"3581933695162448","name":"An1791","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581933695162448","authorIdStr":"3581933695162448"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/182930215","repostId":"2142967204","repostType":4,"isVote":1,"tweetType":1,"viewCount":558,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":182997002,"gmtCreate":1623549884306,"gmtModify":1704205831707,"author":{"id":"3581933695162448","authorId":"3581933695162448","name":"An1791","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581933695162448","authorIdStr":"3581933695162448"},"themes":[],"htmlText":"Awesome","listText":"Awesome","text":"Awesome","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/182997002","repostId":"2142204650","repostType":4,"isVote":1,"tweetType":1,"viewCount":243,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":182903289,"gmtCreate":1623549472041,"gmtModify":1704205807888,"author":{"id":"3581933695162448","authorId":"3581933695162448","name":"An1791","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581933695162448","authorIdStr":"3581933695162448"},"themes":[],"htmlText":"Hmm","listText":"Hmm","text":"Hmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/182903289","repostId":"2142788457","repostType":4,"isVote":1,"tweetType":1,"viewCount":354,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":182997767,"gmtCreate":1623549898659,"gmtModify":1704205832680,"author":{"id":"3581933695162448","authorId":"3581933695162448","name":"An1791","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581933695162448","authorIdStr":"3581933695162448"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/182997767","repostId":"2142204844","repostType":4,"repost":{"id":"2142204844","kind":"news","pubTimestamp":1623431888,"share":"https://ttm.financial/m/news/2142204844?lang=&edition=fundamental","pubTime":"2021-06-12 01:18","market":"us","language":"en","title":"Blackstone, Starwood Deal for Extended Stay Wins Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2142204844","media":"Bloomberg","summary":"(Bloomberg) -- Blackstone Group Inc. and Starwood Capital Group’s takeover of Extended Stay America ","content":"<p><img src=\"https://static.tigerbbs.com/781587d75acac15371617989c7af26cc\" tg-width=\"2000\" tg-height=\"1271\"></p>\n<p>(Bloomberg) -- Blackstone Group Inc. and Starwood Capital Group’s takeover of <a href=\"https://laohu8.com/S/STAY\">Extended Stay America Inc</a>. has been approved by the hotel chain’s shareholders.</p>\n<p>The preliminary results of the vote show that a majority of the shareholders were for the deal at $20.50 a share, according to a statement on Friday.</p>\n<p>The private equity firms agreed to buy Extended Stay in March for $19.50 a share, boosting their offer by $1 per share after opposition from six shareholders, including Tarsadia Capital, which campaigned to block the deal.</p>\n<p>Read more: Extended Stay Sued Over $6 Billion Sale to Blackstone, Starwood</p>\n<p>Tarsadia and some other investors continued to oppose the deal despite the price increase, arguing the sales process was flawed, the timing was wrong, and the standalone prospects for the company were better than the value being offered.</p>\n<p>“While we continue to believe that the board’s process was poorly constructed and that this transaction is not the right outcome for shareholders, we are pleased to have helped secure a better price,” a representative for Tarsadia said in a statement.</p>\n<p>Extended Stay, which caters to construction crews, emergency responders, and other long-term guests, was mostly insulated from a historically bad year for the global lodging industry. Occupancy rates were 73% last year at the 563 hotels that the company owns, compared to 42% for all U.S. hotels.</p>\n<p>Lodging companies have recovered most of the value they lost when the pandemic halted travel, with a Bloomberg index of real estate investment trusts that own hotels is down less than 6% from February 2020.</p>\n<p>Hotel demand, on the other hand, will take years to recover. Leisure travel is bouncing back this summer as vaccinated Americans make up for lost vacations, but sluggish corporate travel means occupancy rates won’t return to 2019 levels until 2023, according to lodging analytics firm STR. Room prices will take even longer to rebound.</p>\n<p>Blackstone, meanwhile, is aiming to profit from Extended Stay for the third time. The private equity giant bought the company in 2004 and sold it three years later. The prolific real estate investor, which has described travel as <a href=\"https://laohu8.com/S/AONE\">one</a> of its highest conviction themes, was part of a group that bought Extended Stay out of bankruptcy in 2010 and eventually took it public.</p>\n<p>“They keep making money on it,” said Michael Bellisario, an analyst at Robert W. Baird &amp; Co. “Isn’t that the simple answer?”</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Blackstone, Starwood Deal for Extended Stay Wins Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBlackstone, Starwood Deal for Extended Stay Wins Approval\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-12 01:18 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/blackstone-starwood-deal-extended-stay-165852088.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Bloomberg) -- Blackstone Group Inc. and Starwood Capital Group’s takeover of Extended Stay America Inc. has been approved by the hotel chain’s shareholders.\nThe preliminary results of the vote show ...</p>\n\n<a href=\"https://finance.yahoo.com/news/blackstone-starwood-deal-extended-stay-165852088.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BX":"黑石","STAY":"Extended Stay America Inc"},"source_url":"https://finance.yahoo.com/news/blackstone-starwood-deal-extended-stay-165852088.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2142204844","content_text":"(Bloomberg) -- Blackstone Group Inc. and Starwood Capital Group’s takeover of Extended Stay America Inc. has been approved by the hotel chain’s shareholders.\nThe preliminary results of the vote show that a majority of the shareholders were for the deal at $20.50 a share, according to a statement on Friday.\nThe private equity firms agreed to buy Extended Stay in March for $19.50 a share, boosting their offer by $1 per share after opposition from six shareholders, including Tarsadia Capital, which campaigned to block the deal.\nRead more: Extended Stay Sued Over $6 Billion Sale to Blackstone, Starwood\nTarsadia and some other investors continued to oppose the deal despite the price increase, arguing the sales process was flawed, the timing was wrong, and the standalone prospects for the company were better than the value being offered.\n“While we continue to believe that the board’s process was poorly constructed and that this transaction is not the right outcome for shareholders, we are pleased to have helped secure a better price,” a representative for Tarsadia said in a statement.\nExtended Stay, which caters to construction crews, emergency responders, and other long-term guests, was mostly insulated from a historically bad year for the global lodging industry. Occupancy rates were 73% last year at the 563 hotels that the company owns, compared to 42% for all U.S. hotels.\nLodging companies have recovered most of the value they lost when the pandemic halted travel, with a Bloomberg index of real estate investment trusts that own hotels is down less than 6% from February 2020.\nHotel demand, on the other hand, will take years to recover. Leisure travel is bouncing back this summer as vaccinated Americans make up for lost vacations, but sluggish corporate travel means occupancy rates won’t return to 2019 levels until 2023, according to lodging analytics firm STR. Room prices will take even longer to rebound.\nBlackstone, meanwhile, is aiming to profit from Extended Stay for the third time. The private equity giant bought the company in 2004 and sold it three years later. The prolific real estate investor, which has described travel as one of its highest conviction themes, was part of a group that bought Extended Stay out of bankruptcy in 2010 and eventually took it public.\n“They keep making money on it,” said Michael Bellisario, an analyst at Robert W. Baird & Co. “Isn’t that the simple answer?”","news_type":1},"isVote":1,"tweetType":1,"viewCount":308,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":182994620,"gmtCreate":1623549868760,"gmtModify":1704205830737,"author":{"id":"3581933695162448","authorId":"3581933695162448","name":"An1791","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581933695162448","authorIdStr":"3581933695162448"},"themes":[],"htmlText":"Alright","listText":"Alright","text":"Alright","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/182994620","repostId":"2142204450","repostType":4,"repost":{"id":"2142204450","kind":"news","pubTimestamp":1623436495,"share":"https://ttm.financial/m/news/2142204450?lang=&edition=fundamental","pubTime":"2021-06-12 02:34","market":"us","language":"en","title":"Amazon Pushes More Into Top-Tier Sports With French Soccer","url":"https://stock-news.laohu8.com/highlight/detail?id=2142204450","media":"Bloomberg","summary":"(Bloomberg) -- Amazon.com Inc. secured broadcast rights to most of France’s biggest soccer competiti","content":"<p>(Bloomberg) -- Amazon.com Inc. secured broadcast rights to most of France’s biggest soccer competition, prompting local pay-TV giant Canal+ to walk away from the league.</p>\n<p>France’s LFP soccer body awarded more than 300 top-flight Ligue 1 games to Amazon and 76 to Canal+ on Friday after the previous rights holder, Spain’s Mediapro, ended its contract early.</p>\n<p>Canal+ said it “regretted the LFP’s decision to choose Amazon’s proposal to the detriment of its historic partners Canal+ and BeIn Sports” and said it would no longer show league matches. That leaves a financing hole to fill for the French soccer authorities, since Canal+ was due to show some of the most-watched, expensive games.</p>\n<p>The award is the latest signal that Amazon is ready to bid for some of the most expensive sports rights to boost demand for its Prime Video platform. Amazon agreed to pay about 275 million euros ($333 million) a year for the matches it has secured, according to a person familiar with the negotiations.</p>\n<p>That’s a fraction of the sum Mediapro agreed to pay for the package before it handed the rights back, and is less than what Canal+ was paying for the rights to the 20% of top games it’s sub-licensing from BeIN. Amazon declined to comment on how much it paid. Mediapro’s deal to broadcast about 80% of the top French soccer games was valued at about 800 million euros annually, according to media reports.</p>\n<p>The Amazon deal “signals a new era for Ligue 1 as its matches are distributed on a digital streaming service for the very first time,” the e-commerce giant said in a statement. The Amazon Prime subscription service, which includes the Prime Video streaming platform, counts more than 200 million members worldwide. The Seattle-based company has already secured select games in England’s Premier League and pushed deeper into sports coverage in the U.S., acquiring rights to NFL games.</p>\n<p>A spokeswoman for Vivendi SE’s Canal+ declined to say more about the company’s decision to relinquish its rights.</p>\n<p>French soccer authorities have been desperate to inject fresh funds into the country’s struggling clubs and ensure local fans can continue to watch their domestic league featuring global stars such as Neymar da Silva Santos and Kylian Mbappe.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Amazon Pushes More Into Top-Tier Sports With French Soccer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAmazon Pushes More Into Top-Tier Sports With French Soccer\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-12 02:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/amazon-pushes-more-top-tier-183455672.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Bloomberg) -- Amazon.com Inc. secured broadcast rights to most of France’s biggest soccer competition, prompting local pay-TV giant Canal+ to walk away from the league.\nFrance’s LFP soccer body ...</p>\n\n<a href=\"https://finance.yahoo.com/news/amazon-pushes-more-top-tier-183455672.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"09086":"华夏纳指-U","QNETCN":"纳斯达克中美互联网老虎指数","AMZN":"亚马逊","03086":"华夏纳指"},"source_url":"https://finance.yahoo.com/news/amazon-pushes-more-top-tier-183455672.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2142204450","content_text":"(Bloomberg) -- Amazon.com Inc. secured broadcast rights to most of France’s biggest soccer competition, prompting local pay-TV giant Canal+ to walk away from the league.\nFrance’s LFP soccer body awarded more than 300 top-flight Ligue 1 games to Amazon and 76 to Canal+ on Friday after the previous rights holder, Spain’s Mediapro, ended its contract early.\nCanal+ said it “regretted the LFP’s decision to choose Amazon’s proposal to the detriment of its historic partners Canal+ and BeIn Sports” and said it would no longer show league matches. That leaves a financing hole to fill for the French soccer authorities, since Canal+ was due to show some of the most-watched, expensive games.\nThe award is the latest signal that Amazon is ready to bid for some of the most expensive sports rights to boost demand for its Prime Video platform. Amazon agreed to pay about 275 million euros ($333 million) a year for the matches it has secured, according to a person familiar with the negotiations.\nThat’s a fraction of the sum Mediapro agreed to pay for the package before it handed the rights back, and is less than what Canal+ was paying for the rights to the 20% of top games it’s sub-licensing from BeIN. Amazon declined to comment on how much it paid. Mediapro’s deal to broadcast about 80% of the top French soccer games was valued at about 800 million euros annually, according to media reports.\nThe Amazon deal “signals a new era for Ligue 1 as its matches are distributed on a digital streaming service for the very first time,” the e-commerce giant said in a statement. The Amazon Prime subscription service, which includes the Prime Video streaming platform, counts more than 200 million members worldwide. The Seattle-based company has already secured select games in England’s Premier League and pushed deeper into sports coverage in the U.S., acquiring rights to NFL games.\nA spokeswoman for Vivendi SE’s Canal+ declined to say more about the company’s decision to relinquish its rights.\nFrench soccer authorities have been desperate to inject fresh funds into the country’s struggling clubs and ensure local fans can continue to watch their domestic league featuring global stars such as Neymar da Silva Santos and Kylian Mbappe.","news_type":1},"isVote":1,"tweetType":1,"viewCount":280,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":182995669,"gmtCreate":1623549854351,"gmtModify":1704205829280,"author":{"id":"3581933695162448","authorId":"3581933695162448","name":"An1791","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581933695162448","authorIdStr":"3581933695162448"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/182995669","repostId":"2142025622","repostType":4,"repost":{"id":"2142025622","kind":"news","pubTimestamp":1623442528,"share":"https://ttm.financial/m/news/2142025622?lang=&edition=fundamental","pubTime":"2021-06-12 04:15","market":"us","language":"en","title":"Biotech Finds Market Love at Last as Meme Traders, FDA Converge","url":"https://stock-news.laohu8.com/highlight/detail?id=2142025622","media":"Bloomberg","summary":"(Bloomberg) -- Unloved biotech stocks posted the best week since November, fueled by a controversial","content":"<p><img src=\"https://static.tigerbbs.com/8cda5e1416d8765a6009019a2442b35a\" tg-width=\"1200\" tg-height=\"675\"></p>\n<p>(Bloomberg) -- Unloved biotech stocks posted the best week since November, fueled by a controversial regulatory decision and a legion of Reddit fans, burning a bunch of short sellers along the way. Now investors are taking a second look at the sector.</p>\n<p>With biotech having trailed the broader market for the past three months and chock full of companies that have been the focus of short sellers, it was catnip for the Reddit crowd. Indeed, the price action wrought havoc across the health-care sector after shorts lost over $465 million on Clover Health Investments Corp. in a single day as the stock nearly doubled.</p>\n<p>The moves weren’t just about amateur traders or punishing the shorts. Specialists who live and breathe biotech received two of three critical updates that have been hailed as the impetus for a broad return of investor interest. That includes approval from the Food and Drug Administration of an Alzheimer’s disease drug from Biogen Inc.</p>\n<p>“One of the clouds overhanging the sector went away this week, it’s a very good sign,” Brad Loncar, chief executive officer of Loncar Investments, said of the FDA decision.</p>\n<p>Monday’s decision by the FDA to approve Aduhelm, the first new medicine for the disease in decades, came despite mixed clinical trials, stunning analysts and buoying the sector. More than 15 million shares in the $11 billion <a href=\"https://laohu8.com/S/EEME\">iShares</a> Nasdaq Biotechnology ETF (IBB) changed hands, the highest daily level since June 2017. The index ended the week up 6%.</p>\n<p>It wasn’t all good news for these drugmakers. Aduhelm’s $56,000 a year price tag and a setback for Vertex Pharmaceuticals Inc. tempered the rally. The cost of the Biogen drug renewed concern about a regulatory clampdown on pricing, while Vertex announced that it had halted development of a liver disease treatment that the company said was unlikely to have a clinical benefit for patients. Shares of the drug developer plunged 11% on Friday and it’s the worst performer among large-cap biotechs, falling 18% so far this year.</p>\n<p>There’s <a href=\"https://laohu8.com/S/AONE\">one</a> more key readout biotech investors are waiting on: results from a trial in major depression from Biogen and its partner <a href=\"https://laohu8.com/S/SAGE\">Sage Therapeutics</a> Inc. With a win for Biogen and a loss for Vertex, the Biogen-Sage results could very well determine which direction biotech goes next, according to RBC analyst Brian Abrahams. The data are expected by the end of June.</p>\n<p>A recent Goldman Sachs survey of 75 investors at the bank’s health-care conference highlights the ongoing uncertainty, with 47% saying the sector would outperform over the second half of the year while the rest were evenly split between expecting health stocks to underperform or move in-line with the broader market.</p>\n<p><b>M&amp;A Hopes</b></p>\n<p>Vertex’s recent failure also came with a silver lining: the potential for a deal to bolster its pipeline. “Management has signaled a new openness to later-stage deals, and the shelving of VX-864 may now force its hand,” Bloomberg Intelligence analyst Marc Engelsgjerd wrote in a note.</p>\n<p>The pace of deals in the first half can determine the direction of biotechs for the rest of 2021, with years that start off with five or more deals over $500 million usually driving the outperformance of nearly 4% for the Nasdaq Biotech index, according to JPMorgan’s analysis.</p>\n<p>As biotech specialists weighed the catalysts for further gains, an 86% jump for Chamath Palihapitiya-backed health insurer Clover drove interest toward once high-flying biotechs with highly shorted floats and mediocre analyst ratings. <a href=\"https://laohu8.com/S/INO\">Inovio Pharmaceuticals Inc</a>., which recently lost U.S. government funding for its Covid shot, and <a href=\"https://laohu8.com/S/CLVS\">Clovis Oncology</a> Inc., a fallen former M&amp;A target with a disappointing cancer drug, popped this week as day traders targeted short-squeeze candidates.</p>\n<p>Retail traders have also been driving triple-digit and even quadruple-digit gains in obscure biotech names like Ocugen Inc., a drug developer with plans to bring a Covid-19 vaccine to the U.S., and <a href=\"https://laohu8.com/S/SAVA\">Cassava Sciences Inc</a>., a 20-year old biotech whose main product isn’t yet in the final stages of testing.</p>\n<p>Loncar at least is unfazed by biotechs joining the meme parade. “Professionals understand what the true intrinsic value of a biotech is,” he said in an interview. “Unlike GameStop or AMC, a biotech either has good science or it doesn’t.”</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biotech Finds Market Love at Last as Meme Traders, FDA Converge</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiotech Finds Market Love at Last as Meme Traders, FDA Converge\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-12 04:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/biotech-finds-market-love-last-201528495.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Bloomberg) -- Unloved biotech stocks posted the best week since November, fueled by a controversial regulatory decision and a legion of Reddit fans, burning a bunch of short sellers along the way. ...</p>\n\n<a href=\"https://finance.yahoo.com/news/biotech-finds-market-love-last-201528495.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VRTX":"福泰制药","BIIB":"渤健公司"},"source_url":"https://finance.yahoo.com/news/biotech-finds-market-love-last-201528495.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2142025622","content_text":"(Bloomberg) -- Unloved biotech stocks posted the best week since November, fueled by a controversial regulatory decision and a legion of Reddit fans, burning a bunch of short sellers along the way. Now investors are taking a second look at the sector.\nWith biotech having trailed the broader market for the past three months and chock full of companies that have been the focus of short sellers, it was catnip for the Reddit crowd. Indeed, the price action wrought havoc across the health-care sector after shorts lost over $465 million on Clover Health Investments Corp. in a single day as the stock nearly doubled.\nThe moves weren’t just about amateur traders or punishing the shorts. Specialists who live and breathe biotech received two of three critical updates that have been hailed as the impetus for a broad return of investor interest. That includes approval from the Food and Drug Administration of an Alzheimer’s disease drug from Biogen Inc.\n“One of the clouds overhanging the sector went away this week, it’s a very good sign,” Brad Loncar, chief executive officer of Loncar Investments, said of the FDA decision.\nMonday’s decision by the FDA to approve Aduhelm, the first new medicine for the disease in decades, came despite mixed clinical trials, stunning analysts and buoying the sector. More than 15 million shares in the $11 billion iShares Nasdaq Biotechnology ETF (IBB) changed hands, the highest daily level since June 2017. The index ended the week up 6%.\nIt wasn’t all good news for these drugmakers. Aduhelm’s $56,000 a year price tag and a setback for Vertex Pharmaceuticals Inc. tempered the rally. The cost of the Biogen drug renewed concern about a regulatory clampdown on pricing, while Vertex announced that it had halted development of a liver disease treatment that the company said was unlikely to have a clinical benefit for patients. Shares of the drug developer plunged 11% on Friday and it’s the worst performer among large-cap biotechs, falling 18% so far this year.\nThere’s one more key readout biotech investors are waiting on: results from a trial in major depression from Biogen and its partner Sage Therapeutics Inc. With a win for Biogen and a loss for Vertex, the Biogen-Sage results could very well determine which direction biotech goes next, according to RBC analyst Brian Abrahams. The data are expected by the end of June.\nA recent Goldman Sachs survey of 75 investors at the bank’s health-care conference highlights the ongoing uncertainty, with 47% saying the sector would outperform over the second half of the year while the rest were evenly split between expecting health stocks to underperform or move in-line with the broader market.\nM&A Hopes\nVertex’s recent failure also came with a silver lining: the potential for a deal to bolster its pipeline. “Management has signaled a new openness to later-stage deals, and the shelving of VX-864 may now force its hand,” Bloomberg Intelligence analyst Marc Engelsgjerd wrote in a note.\nThe pace of deals in the first half can determine the direction of biotechs for the rest of 2021, with years that start off with five or more deals over $500 million usually driving the outperformance of nearly 4% for the Nasdaq Biotech index, according to JPMorgan’s analysis.\nAs biotech specialists weighed the catalysts for further gains, an 86% jump for Chamath Palihapitiya-backed health insurer Clover drove interest toward once high-flying biotechs with highly shorted floats and mediocre analyst ratings. Inovio Pharmaceuticals Inc., which recently lost U.S. government funding for its Covid shot, and Clovis Oncology Inc., a fallen former M&A target with a disappointing cancer drug, popped this week as day traders targeted short-squeeze candidates.\nRetail traders have also been driving triple-digit and even quadruple-digit gains in obscure biotech names like Ocugen Inc., a drug developer with plans to bring a Covid-19 vaccine to the U.S., and Cassava Sciences Inc., a 20-year old biotech whose main product isn’t yet in the final stages of testing.\nLoncar at least is unfazed by biotechs joining the meme parade. “Professionals understand what the true intrinsic value of a biotech is,” he said in an interview. “Unlike GameStop or AMC, a biotech either has good science or it doesn’t.”","news_type":1},"isVote":1,"tweetType":1,"viewCount":316,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":182999922,"gmtCreate":1623549710566,"gmtModify":1704205820190,"author":{"id":"3581933695162448","authorId":"3581933695162448","name":"An1791","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581933695162448","authorIdStr":"3581933695162448"},"themes":[],"htmlText":"Sure","listText":"Sure","text":"Sure","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/182999922","repostId":"2142024122","repostType":4,"repost":{"id":"2142024122","kind":"news","pubTimestamp":1623437876,"share":"https://ttm.financial/m/news/2142024122?lang=&edition=fundamental","pubTime":"2021-06-12 02:57","market":"us","language":"en","title":"Moderna Says No Link Between COVID-19 Jab And Heart Inflammation","url":"https://stock-news.laohu8.com/highlight/detail?id=2142024122","media":"Benzinga","summary":"Moderna Inc (NASDAQ: MRNA) says there is no “causal association” between its COVID-19 vaccine and ca","content":"<p><img src=\"https://static.tigerbbs.com/d1f671326f56d69d77095c4224c4a60a\" tg-width=\"600\" tg-height=\"400\" referrerpolicy=\"no-referrer\"></p>\n<p><b>Moderna Inc</b>&nbsp;(NASDAQ: MRNA) says there is no “causal association” between its COVID-19 vaccine and cases of myocarditis or pericarditis,&nbsp;based on a review of safety data.</p>\n<p>The Centers for Disease Control and Prevention (CDC) has identified 216 cases of heart inflammation after the first dose of an mRNA shot and another 573 cases after the second dose,&nbsp;Bloomberg reported.</p>\n<p>The median age of people with myocarditis or pericarditis following the first dose was 30 and 24 in the second-dose cases. There were 475 cases among people under 30.</p>\n<p>U.S. public health advisers will meet later this month to discuss a potential link between messenger RNA technology-based COVID-19 shots and heart inflammation.</p>\n<p>The technology is used by Moderna’s vaccine and&nbsp;<b>Pfizer Inc&nbsp;</b>(NYSE: PFE) -&nbsp;<b><a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>&nbsp;</b>(NASDAQ: BNTX).</p>\n<p>Moderna said it “will continue to monitor these reports closely and is actively working with public health and regulatory authorities to further assess this issue.”</p>\n<p>Earlier this month,&nbsp;Israel’s Health Ministry also reportedly found&nbsp;a small number of heart inflammation cases, observed mainly in young men who received the Pfizer COVID-19 vaccine in Israel, were likely linked to their vaccination.</p>\n<p><b>Price Action:</b>&nbsp;MRNA shares are down 0.59% at $215.73 during the market session on the last check Friday.</p>\n<p></p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Says No Link Between COVID-19 Jab And Heart Inflammation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Says No Link Between COVID-19 Jab And Heart Inflammation\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-12 02:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/moderna-says-no-between-covid-185756853.html><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna Inc (NASDAQ: MRNA) says there is no “causal association” between its COVID-19 vaccine and cases of myocarditis or pericarditis, based on a review of safety data.\nThe Centers for Disease ...</p>\n\n<a href=\"https://finance.yahoo.com/news/moderna-says-no-between-covid-185756853.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","PFE":"辉瑞","08237":"华星控股"},"source_url":"https://finance.yahoo.com/news/moderna-says-no-between-covid-185756853.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2142024122","content_text":"Moderna Inc (NASDAQ: MRNA) says there is no “causal association” between its COVID-19 vaccine and cases of myocarditis or pericarditis, based on a review of safety data.\nThe Centers for Disease Control and Prevention (CDC) has identified 216 cases of heart inflammation after the first dose of an mRNA shot and another 573 cases after the second dose, Bloomberg reported.\nThe median age of people with myocarditis or pericarditis following the first dose was 30 and 24 in the second-dose cases. There were 475 cases among people under 30.\nU.S. public health advisers will meet later this month to discuss a potential link between messenger RNA technology-based COVID-19 shots and heart inflammation.\nThe technology is used by Moderna’s vaccine and Pfizer Inc (NYSE: PFE) - BioNTech SE (NASDAQ: BNTX).\nModerna said it “will continue to monitor these reports closely and is actively working with public health and regulatory authorities to further assess this issue.”\nEarlier this month, Israel’s Health Ministry also reportedly found a small number of heart inflammation cases, observed mainly in young men who received the Pfizer COVID-19 vaccine in Israel, were likely linked to their vaccination.\nPrice Action: MRNA shares are down 0.59% at $215.73 during the market session on the last check Friday.","news_type":1},"isVote":1,"tweetType":1,"viewCount":283,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":182904605,"gmtCreate":1623549665207,"gmtModify":1704205816637,"author":{"id":"3581933695162448","authorId":"3581933695162448","name":"An1791","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581933695162448","authorIdStr":"3581933695162448"},"themes":[],"htmlText":"Shine","listText":"Shine","text":"Shine","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/182904605","repostId":"2142342202","repostType":4,"repost":{"id":"2142342202","kind":"news","pubTimestamp":1623441702,"share":"https://ttm.financial/m/news/2142342202?lang=&edition=fundamental","pubTime":"2021-06-12 04:01","market":"us","language":"en","title":"Keystone-Quashing Activists Demand Biden Block Other Pipelines","url":"https://stock-news.laohu8.com/highlight/detail?id=2142342202","media":"Bloomberg","summary":"(Bloomberg) -- Environmentalists emboldened by this week’s defeat of Keystone XL are pressuring Pres","content":"<p><img src=\"https://static.tigerbbs.com/6d6e731cd39779c3ffc566518249bc07\" tg-width=\"2000\" tg-height=\"1333\"></p>\n<p>(Bloomberg) -- Environmentalists emboldened by this week’s defeat of Keystone XL are pressuring President Joe Biden to revoke permits for other oil and gas pipelines, warning their votes depend on the administration blocking fossil fuel infrastructure.</p>\n<p>“If you need and want us -- as I know the Biden team does -- to come out in stronger numbers for 2022, then you have to do right by our community,” Jane Kleeb, the president of Bold Alliance, who spent more than a decade battling TC Energy Corp.’s Keystone XL, said in a call with reporters Friday. “You have to stand up to these big oil and fracked-gas pipelines and say ‘no more.’”</p>\n<p>Pipelines have been a focal point in the fight against climate change, putting leaders such as Biden and Canada’s Justin Trudeau in a tough spot as they pledge to help cut global carbon dioxide emissions at a Group of Seven summit in the U.K. The U.S. is the world’s biggest producer and consumer of oil, and it’s still unclear how plans to wean Americans off gasoline will pan out. Canada holds the world’s third-largest crude reserves and its economy benefits enormously from their development.</p>\n<p>Environmentalists and indigenous groups in both countries are putting mounting pressure on the two leaders to stop pipeline developments, with protests in Minnesota against Canadian giant <a href=\"https://laohu8.com/S/EBPPF\">Enbridge Inc.</a>’s expansion of its Line 3 oil-sands conduit turning violent this week.</p>\n<p>Other projects activists are targeting include <a href=\"https://laohu8.com/S/ET\">Energy Transfer LP</a>’s Dakota Access pipeline, which has been shipping crude from North Dakota’s Bakken oil field to Illinois for four years, and the proposed Byhalia Connection Pipeline, a joint venture between Plains All American Pipeline LP and Valero Energy Corp. to carry oil from Memphis to Mississippi.</p>\n<p>The Enbridge project, permitted by the Army Corps of Engineers under former President Donald Trump, involves the replacement and expansion of an existing pipeline, which will enable it to carry 760,000 barrels per day of Canadian crude across about 350 miles on the U.S. side.</p>\n<p>Opponents say it imperils indigenous land and watersheds throughout Minnesota, and they argue it is not compatible with Biden’s ambitions to combat climate change.</p>\n<p>About 200 anti-pipeline activists were arrested after clashes with law enforcement along Line 3’s route through the state earlier this week, in an episode recalling altercations over the Dakota Access Pipeline in North Dakota. Activists are still camped at multiple spots along the pipeline’s path, with Winona La <a href=\"https://laohu8.com/S/DEX.AU\">Duke</a>, executive director of Honor the Earth, vowing to keep up the pressure. “We will be on the rivers -- protecting our rivers -- as long as needed,” she said.</p>\n<p>Enbridge spokeswoman Tracie Kenyon said the protests are not impacting construction. “Our main focus is the safety of all involved -- our workers, first responders and the protesters themselves,” Kenyon said. “We respect everyone’s right to peacefully and lawfully protest. This project is about safety, and we remain fully committed to its timely completion.”</p>\n<p>Environmentalists want Biden to direct the Army Corps of Engineers to revoke a critical water-crossing permit for Line 3. But doing so could spur a backlash from Canadian politicians, especially following the president’s rejection of Keystone XL in January. Trudeau personally announced the authorization of Line 3 in 2016.</p>\n<p>Sierra Club Executive Director Michael Brune said the administration has displayed an “inconsistent commitment” to addressing the issue and now faces a test: “Will these Trump pipelines become Biden pipelines? Will this administration fully meet its responsibility to respond to the climate crisis?”</p>\n<p>“This is a movement that has helped to elect this president by knocking on millions of doors, making millions of phone calls, sending messages, donating -- doing everything that it can to shift our country and to shift our politics,” Brune said. “What we need is a president who is not working to defend American oil interests -- who is not working to defend Canadian oil interests but is working to defend our people, our native communities, our water and our climate.”</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Keystone-Quashing Activists Demand Biden Block Other Pipelines</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKeystone-Quashing Activists Demand Biden Block Other Pipelines\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-12 04:01 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/keystone-quashing-activists-demand-biden-200142119.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Bloomberg) -- Environmentalists emboldened by this week’s defeat of Keystone XL are pressuring President Joe Biden to revoke permits for other oil and gas pipelines, warning their votes depend on the...</p>\n\n<a href=\"https://finance.yahoo.com/news/keystone-quashing-activists-demand-biden-200142119.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"EBPPF":"Enbridge Inc.","ENB":"安桥"},"source_url":"https://finance.yahoo.com/news/keystone-quashing-activists-demand-biden-200142119.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2142342202","content_text":"(Bloomberg) -- Environmentalists emboldened by this week’s defeat of Keystone XL are pressuring President Joe Biden to revoke permits for other oil and gas pipelines, warning their votes depend on the administration blocking fossil fuel infrastructure.\n“If you need and want us -- as I know the Biden team does -- to come out in stronger numbers for 2022, then you have to do right by our community,” Jane Kleeb, the president of Bold Alliance, who spent more than a decade battling TC Energy Corp.’s Keystone XL, said in a call with reporters Friday. “You have to stand up to these big oil and fracked-gas pipelines and say ‘no more.’”\nPipelines have been a focal point in the fight against climate change, putting leaders such as Biden and Canada’s Justin Trudeau in a tough spot as they pledge to help cut global carbon dioxide emissions at a Group of Seven summit in the U.K. The U.S. is the world’s biggest producer and consumer of oil, and it’s still unclear how plans to wean Americans off gasoline will pan out. Canada holds the world’s third-largest crude reserves and its economy benefits enormously from their development.\nEnvironmentalists and indigenous groups in both countries are putting mounting pressure on the two leaders to stop pipeline developments, with protests in Minnesota against Canadian giant Enbridge Inc.’s expansion of its Line 3 oil-sands conduit turning violent this week.\nOther projects activists are targeting include Energy Transfer LP’s Dakota Access pipeline, which has been shipping crude from North Dakota’s Bakken oil field to Illinois for four years, and the proposed Byhalia Connection Pipeline, a joint venture between Plains All American Pipeline LP and Valero Energy Corp. to carry oil from Memphis to Mississippi.\nThe Enbridge project, permitted by the Army Corps of Engineers under former President Donald Trump, involves the replacement and expansion of an existing pipeline, which will enable it to carry 760,000 barrels per day of Canadian crude across about 350 miles on the U.S. side.\nOpponents say it imperils indigenous land and watersheds throughout Minnesota, and they argue it is not compatible with Biden’s ambitions to combat climate change.\nAbout 200 anti-pipeline activists were arrested after clashes with law enforcement along Line 3’s route through the state earlier this week, in an episode recalling altercations over the Dakota Access Pipeline in North Dakota. Activists are still camped at multiple spots along the pipeline’s path, with Winona La Duke, executive director of Honor the Earth, vowing to keep up the pressure. “We will be on the rivers -- protecting our rivers -- as long as needed,” she said.\nEnbridge spokeswoman Tracie Kenyon said the protests are not impacting construction. “Our main focus is the safety of all involved -- our workers, first responders and the protesters themselves,” Kenyon said. “We respect everyone’s right to peacefully and lawfully protest. This project is about safety, and we remain fully committed to its timely completion.”\nEnvironmentalists want Biden to direct the Army Corps of Engineers to revoke a critical water-crossing permit for Line 3. But doing so could spur a backlash from Canadian politicians, especially following the president’s rejection of Keystone XL in January. Trudeau personally announced the authorization of Line 3 in 2016.\nSierra Club Executive Director Michael Brune said the administration has displayed an “inconsistent commitment” to addressing the issue and now faces a test: “Will these Trump pipelines become Biden pipelines? Will this administration fully meet its responsibility to respond to the climate crisis?”\n“This is a movement that has helped to elect this president by knocking on millions of doors, making millions of phone calls, sending messages, donating -- doing everything that it can to shift our country and to shift our politics,” Brune said. “What we need is a president who is not working to defend American oil interests -- who is not working to defend Canadian oil interests but is working to defend our people, our native communities, our water and our climate.”","news_type":1},"isVote":1,"tweetType":1,"viewCount":199,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}